Teplizumab: an FDA- approved drug, marks milestone in treatment of type 1 diabetes
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20233870Keywords:
Diabetes type-1 , Teplizumab, FDAAbstract
Diabetes type-1 is a chronic disease characterized by immune-mediated destruction of insulin-producing beta cells in the pancreas. It progresses through distinct stages at varying rates, with stage 1 being β-cell autoimmunity with normal blood sugar, stage 2 being β-cell autoimmunity with dysglycemia, and stage 3 being symptomatic disease onset.
Metrics
References
Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-74.
IDF. Diabetes Atlas, 2019. Available at: http://www.diabetesatlas.org. Accessed on 18 February 2022.
Diabetes. Symlin (Pramlintide), 2018. Available at: https://www.diabetes.co.uk/diabetesmedication/symlin-pramlintide.html. Accessed on 18 February 2022.
Pharmacy Times. Tzield From Provention Bio, Inc, 2023. Available at: https://investors.proventionbio. com/202211byadultand-pediatric-patientsandolder-withStage-. Accessed on 18 February 2022.
Pharmacy Times.Clinical Overview: Teplizumab for Type 1 Diabetes Mellitus, 2022. Available at: https://www.pharmacytimes.com/view/cliniciewteplizumab-for-type-1-diabetes-mellitus. Accessed on 18 February 2022.
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-13.
Yale Medicine. Type 1 Diabetes Drug, Teplizumab, Has Additional Benefits, New Study Shows, 2022. Available at: https://www.yalemedicine.org/ news/teplizumabnew-diabetes-drug. Accessed on 18 February 2022.
Rx list. Teplizumab, 2023. Available at: https://www.rxlist.com/tzield_teplizumab/drugscondition.htm. Accessed on 18 February 2022.
